V. Pyon

Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

Kwok-Kin Wong, Haiquan Chen, C. Peng, 2021, Cancer Research.

ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer

C. Perou, C. Rudin, G. Freeman, 2021, Nature Cancer.

Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy

Joshua D. Campbell, A. Bass, Kwok-Kin Wong, 2020, Clinical Cancer Research.

In vivo epigenetic CRISPR screen identifies Asf1a as an immunotherapeutic target in Kras-mutant lung adenocarcinoma.

G. Freeman, P. Hammerman, Kwok-Kin Wong, 2019, Cancer discovery.

Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

Mousheng Xu, Kwok-Kin Wong, J. Qi, 2020, Cancer Research.

Title : Targeting HER 2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel 2 Tyrosine Kinase Inhibitor

Kwok-Kin Wong, Haiquan Chen, V. Rivera, 2021 .

CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer.

Dayanne M. Castro, Richard Bonneau, G. Freeman, 2019, Cancer cell.